May. 18 at 5:55 PM
$CTOR I will continue my mildly bullish rant. Asking for an analysis of the numbers in light of the initial December sales, AI spits out the following:
The Quarter-over-Quarter Decline: The sequential drop from
$3.94 million to
$1.67 million reflects the typical pharmaceutical launch curve. Specialty distributors placed major, large-scale initial orders in December 2025 to stock their channels.
Inventory Digestion: During the three months ended March 31, 2026, those distributors were working through that initial December inventory while transition to patient-driven "repeat orders" began taking shape.
Distorted Expectations: This front-loaded revenue in December made the subsequent three-month performance look artificially low to the market, leading to the headline-grabbing revenue miss against initial analyst expectations.
